Pfizer’s under-trial HIV drug available
Our News Bureau – Mumbai
Pfizer announced that it plans to establish a multinational Expanded Access Programme (EAP) to make the investigational CCR5 antagonist maraviroc, currently in ongoing Phase III clinical trials available to HIV/AIDS patients with CCR5-tropic HIV-1, who have limited or no approved treatment options due to resistance or intolerance. Pending regulatory review and approvals of the EAP study protocol, the programme will begin enrolling patients in the next few months, with a target to enrol patients from over 30 countries.
Maraviroc is in a new class of investigational HIV drugs known as CCR5 antagonists, designed to work differently from currently available HIV/AIDS anti-retroviral medicines. Rather than fighting HIV inside white blood cells, CCR5 antagonists prevent the virus from entering cells by blocking its predominant entry route, the CCR5 co-receptor.
The EAP is designed to provide access to maraviroc for patients who in the opinion of the programme investigators, need it to create a viable regimen. “People living with HIV, whose virus is resistant to available therapies have an urgent need for novel medicines,” said John LaMattina, President, Pfizer Global Research and Development. “It is our hope that maraviroc, now in final stages of clinical development, may help those patients who have exhausted treatment options and are not already participating in our clinical studies.”
Pfizer confirmed plans to submit applications for marketing approval in both the US and EU following review of the data from the two Phase III maraviroc registrational trials. These are 24-week studies of Optimised Background Therapy (OBT), with or without maraviroc, in highly treatment experienced patients with CCR5-tropic HIV-1. Pfizer will submit these results expeditiously for presentation at an upcoming HIV conference.
To broaden the programme’s reach, Pfizer is recruiting many investigators with previous EAP experience, as well as HIV clinical experts at centres which have not previously engaged in expanded access initiatives. Study patients will receive open-label maraviroc twice daily in addition to OBT. In some circumstances, the study allows the use of OBT that may contain other investigational anti-retroviral agents in Phase III clinical development.